Navigation Links
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Date:8/19/2007

Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study

involving the systemic delivery of siRNA

FREMONT, Calif., Aug. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today the presentation of positive results from preclinical efficacy studies for its proprietary systemically-administered, siRNA compound, AKIi-5, in acute renal failure (ARF).

In the study, rats treated with a single bolus injection of rat AKIi-5, Quark's proprietary siRNA compound targeting the p53 gene, were significantly protected from ischemia/reperfusion-induced acute kidney injury. The compound was most efficacious when administered within a well-determined time window of 2-4 hours post injury. The study also proved that AKIi-5 has a favorable drug disposition (PK) profile, with short local exposure predominantly to the kidney-exhibiting rapid clearance of the drug post-administration. Quark's preclinical studies to date also indicate that AKIi-5 has a favorable safety profile, with a therapeutic index (toxic dose/effective dose) in rats greater than 250.

Elena Feinstein, M.D., Ph.D., the Company's Chief Scientific Officer, presented the results of the preclinical efficacy studies in a poster session at the Beyond Genome 2007 conference in San Francisco, CA. Quark's poster presentation was based on unpublished data. The studies were performed in collaboration with Bruce A. Molitoris, M.D., Director of the Division of Nephrology and Professor of Medicine at Indiana University School of Medicine, and lead academic investigator in the Quark program.

Daniel Zurr, CEO of Quark, commented, "Our pharmacokinetic, distribution, and toxicity studies indicate that siRNA-mediated, temporary inhibition of p53 by our systemically administered drug, AKIi-5, is a safe and efficient way to treat and prevent acute
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Inc. (NYSE: ALR ) (the "Company") announced ... of its consent solicitations commenced on May 31, 2011 ... "Proposed Modifications") governing its 9.0% Senior Subordinated Notes due ... 2018 (the "8.625% Notes") and 7.875% Senior Notes due ...
... Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, ... scheduled to present at the Wells Fargo Securities Healthcare ... 2011, at The InterContinental Boston. Mr. Renz, presentation is ... Investors planning to attend the conference ...
Cached Medicine Technology:NewCardio to Present at Wells Fargo Securities Healthcare Conference 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 3
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business is ... company announces big discounts on its bamboo mats , ... is the world’s leader in bamboo flooring. According to ... 20, 2015. , The bamboo mats are made from ... All the bamboo strips for the mats are boiled ...
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2
... with one of the most common causes of blindness in ... Researchers from the University of Strathclyde and Stanford University ... age related macular degeneration (AMD), which affects one in 500 ... eight aged over 85. The device would be simpler ...
... 16, 2012)For some patients with muscle-invasive bladder cancer, ... surgical removal of the bladder. They may be ... A large randomized clinical trial published in 2003 ... MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a ...
... will present several landmark studies, including data on treatment ... and predictive models of soft tissue sarcomas, prostate and ... Oncology (ASCO) meeting June 1-5, 2012 in Chicago. ... Age, Race, Lower Income, and ...
... by psychologists at three North American universities, including the ... levels of happiness and meaning from life than non-parents. ... and popular beliefs, suggest that parents are happier caring ... The research also suggests that the benefits of parenthood ...
... Boston have determined that pediatric epilepsy significantly impacts sleep ... study available in Epilepsia , a journal published ... Epilepsy (ILAE), sharing a room or co-sleeping with their ... restful sleep for parents. Over 1% of ...
... HealthDay Reporter , WEDNESDAY, May 16 (HealthDay ... raise the risk of death in patients with heart ... been tied to an increased risk of sudden death ... (Zithromax) might be part of that group, said the ...
Cached Medicine News:Health News:Prosthetic retina offers simple solution to restoring sight 2Health News:Prosthetic retina offers simple solution to restoring sight 3Health News:Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer 2Health News:Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer 3Health News:Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO 2Health News:Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO 3Health News:Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO 4Health News:Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO 5Health News:Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO 6Health News:Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO 7Health News:Parents are happier than non-parents, new research suggests 2Health News:Pediatric epilepsy impacts sleep for the child and parents 2Health News:Study Links Antibiotic to Slight Rise in Heart Patients' Death Risk 2
... has the right product for any patient ... intubated patients to patients with tracheotomies. These ... and critical care applications., ,The Unti-Mist ... patients and staff members. This entire product ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
Indications For Usage: ,Pediatric (recommended tidal volume 70-250ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intend...
Medicine Products: